Part 4 of the Live Beyond the Label four-part series on mandatory folic acid flour fortification
At the end of Part 3, we asked
What did the major studies actually demonstrate, what did they not test, and how will we know whether the UK policy produces the predicted benefits without creating unintended consequences?
These questions matter because scientific evidence is often reduced to a simple headline.
Folic acid reduces neural tube defects.
That statement is supported by important research. It explains why women who are trying to conceive are advised to take folic acid before pregnancy and during its earliest stages.
But it does not answer every question about the policy that will take full effect on 13 December 2026.
Evidence that a defined supplement can help prevent the recurrence of neural tube defects in women at high risk is not identical to evidence about adding folic acid to a staple ingredient consumed by children, men, older adults, supplement users and women throughout every stage of life.
The findings are related, but they are not interchangeable.
At Live Beyond the Label, we believe good public health decisions require more than proving that an intervention can provide a benefit.
They also require examination of the method, dose, target population, cumulative exposure, uncertainties and practical consequences.
The final part of this series looks at where the evidence began, how it has been translated into UK policy and what must happen after implementation.
The Evidence Supporting Folic Acid
Folate, also known as vitamin B9, is essential to normal cell function.
Folic acid is the synthetic form used in most supplements and fortified foods.
UK government guidance states that folic acid helps a baby’s spine develop and reduces the risk of neural tube defects, including spina bifida. Women trying to conceive are advised to take a daily 400-microgram folic acid supplement, ideally beginning three months before pregnancy and continuing for at least its first 12 weeks. That advice will remain in place after mandatory flour fortification begins.
The fact that supplementation remains recommended is important.
Flour fortification is not being presented as a replacement for the established pregnancy advice. It is intended to increase baseline intake across the population, including among women who become pregnant without having taken a supplement beforehand.
Live Beyond the Label is not disputing the recognised preventative role of folic acid.
Our concern is whether evidence supporting that role justifies the particular delivery method selected, and whether the policy will be assessed thoroughly once it begins operating throughout the real food supply.
The Landmark Trial
One of the most influential studies in this area was the MRC Vitamin Study, published in 1991.
It was a randomised, double blind trial conducted through 33 centres in 7 countries.
It enrolled 1,817 women considered at high risk because they had previously experienced a pregnancy affected by a neural tube defect.
Participants were allocated to one of four groups and received either
– Folic acid only
– A mixture of other vitamins only
– Both Folic acid and the other vitamins
– Neither treatment
Among 1,195 completed pregnancies for which the outcome was known, 27 involved a neural tube defect.
Six occurred in the groups receiving folic acid, compared with 21 in the groups not receiving it.
The researchers calculated a 72 per cent protective effect against recurrence.
This was extremely important evidence.
It demonstrated that folic acid supplementation around conception could substantially reduce the recurrence of neural tube defects among women who had already experienced an affected pregnancy.
The trial reported no demonstrable harm from supplementation, while also stating that its ability to detect rare or slight adverse effects was limited.
That final qualification matters.
It does not undermine the result.
It explains the boundaries of what the study could establish.
What the Trial Demonstrated
The MRC Vitamin Study provided strong evidence that folic acid taken around conception could reduce neural tube defect recurrence in a specific high risk group.
Its randomised and double blind design made it particularly valuable because it reduced several sources of bias that can affect observational research.
Its findings supported advice that women with a previous affected pregnancy should receive folic acid before conception.
The result also strengthened the wider public health case for ensuring adequate folate status during the period in which the neural tube develops.
These are substantial findings, and they should not be minimised merely because questions remain about how they were later translated into public policy.
What the Trial Did Not Test
The same study did not directly test
– Mandatory fortification of the entire UK flour supply
– Lifelong consumption beginning in infancy
– Exposure among men or older adults
– The final UK concentration of 250 micrograms per 100 grams of flour
– Intake through bread, cakes, pastries, sauces, soups and ready meals
– Modern combinations of mandatory fortification, voluntary fortification and supplements
– The effect of flour fortification among a representative sample of the whole population
– Rare or slight adverse outcomes with sufficient statistical power
These are not criticisms of the researchers.
A clinical trial can answer only the question it was designed to investigate.
The MRC Vitamin Study examined supplementation around conception among women with a previous neural tube defect affected pregnancy.
It was not designed as a trial of lifelong population wide food fortification.
The authors themselves acknowledged that the study had limited ability to detect rare or slight adverse effects.
Policy decisions often rely on several forms of evidence rather than one trial alone.
These may include clinical trials, nutritional surveys, biological evidence, international experience, risk assessments and mathematical modelling.
The concern arises when the certainty attached to one finding is allowed to spread beyond what that finding directly demonstrated.
Evidence and Policy Are Not the Same Thing
Evidence can establish that an intervention has a beneficial effect.
Policy determines how that benefit will be pursued across society.
Those are related but different decisions.
Once policymakers accepted that improved folate status before and during early pregnancy could reduce neural tube defect risk, they still had to decide
– Which population should be targeted
– Whether to rely on supplements, education, fortification or a combination
– Which food should carry the added nutrient
– Which chemical form should be used
– What concentration should be selected
– Which exemptions should apply
– How cumulative intake should be assessed
– How the effect on non-target groups should be monitored
– What information consumers should receive
– What findings would justify changing the policy
The UK selected non wholemeal common wheat flour because it is widely consumed.
The government estimates that mandatory fortification will reduce neural-tube-defect rates by around 20 per cent.
It also acknowledges that the policy will increase folic acid intake and folate status across the whole population.
That whole population reach is not incidental.
It is the chosen delivery mechanism.
What Can International Experience Tell Us?
UK guidance states that wheat flour fortification with folic acid has been adopted on a mandatory or voluntary basis in more than 60 countries, including the United States, Canada and Australia.
This experience is relevant.
It means the UK is not introducing an entirely unprecedented nutritional intervention.
Evidence from other countries can contribute to understanding changes in folate status, neural tube defect rates and wider health outcomes following fortification.
However, international experience cannot remove the need for UK specific evaluation.
Countries may differ in
– The concentration added
– The foods covered
– Existing voluntary fortification
– Supplement use
– Dietary patterns
– Flour consumption
– Population demographics
– Healthcare systems
– Data collection
– Background folate and vitamin B12 status
Evidence from other countries can inform the UK policy.
It cannot automatically predict every result within the UK’s particular population and food system.
That is why the results observed here must be measured rather than assumed.
Prediction Is Not Observation
Before implementing a population wide policy, researchers must estimate what is likely to happen.
They cannot observe the complete real world effect of a system that does not yet exist.
UK government materials identify stochastic modelling undertaken for Food Standards Scotland among the evidence supporting the fortification decision. The government’s stated expectation is that the chosen policy will reduce neural tube defect rates by about 20 per cent.
Modelling is an important policy tool.
It allows researchers to combine information about dietary consumption, supplement use, existing fortification and demographic differences to predict likely exposure under different scenarios.
But models depend on
– The quality of the information entered
– How representative dietary records are
– Assumptions about future behaviour
– Estimates of flour content
– Expected manufacturer compliance
– Changes in voluntary fortification
– Reported supplement use
– Treatment of high consumers
– Assumptions about products made outside the UK
A model may be carefully designed and still differ from what eventually occurs in everyday life.
This does not mean modelling is unreliable or without value.
It means prediction must be followed by measurement.
What Should Count as Success?
The policy has a stated objective: reducing pregnancies affected by neural tube defects.
Its success should therefore be evaluated against that outcome.
But the assessment should not stop there.
A thorough evaluation should also ask
– Did folate status improve among women before and during early pregnancy?
– Were improvements shared across different communities?
– Did neural-tube-defect rates change by the amount predicted?
– Did supplement use change after fortification began?
– Did manufacturers comply consistently with the required concentration?
– Did voluntary fortification increase, decrease or remain stable?
– Did cumulative intake remain within expected ranges?
– Were particular age groups or dietary groups more highly exposed than predicted?
– Were vitamin B12 status and related biomarkers monitored?
– Did access to affordable unfortified alternatives remain realistic?
– Could consumers identify the presence and quantity of added folic acid?
Some of these questions concern health outcomes.
Others concern implementation, equality, transparency and consumer autonomy.
A public-health policy should not be assessed only by whether it produces its intended benefit. It should also be assessed by whether its assumptions were accurate and whether any unintended effects emerged.
A New UK Wide Study
In March 2026, researchers announced a three-year, £1.9 million study funded by the Medical Research Council to examine the impact of mandatory folic-acid fortification on maternal and infant health.
The project is led by King’s College London, working with the University of Cambridge, the University of Edinburgh, Queen’s University Belfast and the Born in Bradford cohort.
Researchers plan to analyse 2,000 blood samples from women in early pregnancy, covering periods before, during and after the rollout of fortification. Samples will come from London, Bradford, Edinburgh and Belfast.
The study will measure
– Red-blood-cell folate
– Serum folate
– Vitamin B12
– Homocysteine
It will also examine links between fortification, changes in folate related biomarkers and maternal and infant outcomes, including neural tube defects, fetal growth, preterm birth and infant neurodevelopment.
This is valuable and necessary research.
It should provide UK specific evidence about whether the policy improves maternal folate status, whether benefits are distributed fairly and whether changes translate into improved outcomes for mothers and babies.
However, it is not a complete assessment of every consequence of population wide fortification.
Its stated focus is maternal and infant health.
The announced sample consists of women in early pregnancy.
Wider monitoring will still be needed to understand exposure among
– Infants and young children – Teenagers – Men – Older adults –
Regular supplement users – People who consume large quantities of flour-based foods –
– People with low vitamin B12 status –
A strong study addressing one important part of the policy should not be mistaken for complete monitoring of the entire population.
Monitoring Must Be Independent and Visible
Monitoring should not occur only within technical reports that are difficult for the public to locate or interpret.
The results should be published regularly in clear language.
At a minimum, the public should be able to see
– What was measured
– Which population groups were included
– How actual intake compared with predictions
– Whether neural-tube-defect rates changed
– Whether folate and vitamin B12 status changed
– Whether any groups regularly exceeded intake guidance
– Whether voluntary fortification altered cumulative exposure
– Whether unexpected outcomes were identified
– What limitations affected the results
– Whether the policy will remain unchanged, be adjusted or face further review
Transparency after implementation is as important as transparency before it.
If authorities ask the public to trust a nutritional intervention delivered through a staple ingredient, they have a responsibility to show whether the real-world findings support that trust.
What Would Trigger a Review?
A monitoring programme is incomplete unless decision makers explain what they will do with the results.
Publishing data is important, but accountability requires predetermined questions.
For example
– What if the reduction in neural tube defects is smaller than predicted?
– What if some groups receive less benefit than others?
– What if supplement use falls because people incorrectly believe fortified flour has replaced pregnancy guidance?
– What if intake among particular groups is higher than expected?
– What if vitamin B12-related concerns emerge?
– What if voluntary fortification expands and changes cumulative exposure?
– What if meaningful unfortified alternatives become difficult to obtain?
These are not predictions that something will go wrong.
They are reasonable questions for any policy that affects a population through the everyday food supply.
A credible review process should explain what evidence would lead to
– Better public information – Changes to labelling – Restrictions on voluntary fortification –
– Alteration of the mandatory concentration – Expanded monitoring –
– Revised supplement guidance – A formal reconsideration of the policy –
Without defined review points, monitoring risks becoming observation without accountability.
The Wider Population Still Matters
The policy is principally intended to benefit pregnancies during a narrow and important stage of development.
The route chosen to achieve that benefit reaches far beyond pregnancy.
Children, men, older adults and women who cannot or do not intend to become pregnant may consume the added folic acid through ordinary foods.
That does not prove they will be harmed.
It does mean their exposure should be considered and monitored.
The government states that, based on the available evidence, adding folic acid to flour is not associated with health concerns.
Its guidance also acknowledges that mandatory fortification will operate alongside foods already fortified voluntarily, including breakfast cereals.
Live Beyond the Label’s position is that reassurance based on existing evidence must be accompanied by a commitment to test whether actual exposure matches the assumptions on which that reassurance rests.
The correct response to uncertainty is not alarm.
It is measurement, openness and willingness to review.
The Live Beyond the Label Position
Across this four-part series, we have recognised several facts.
Folic acid taken before conception and during early pregnancy can reduce the risk of some neural tube defects.
Many pregnancies are unplanned, and supplementation may not begin before the neural tube develops.
Flour was selected because it is consumed widely and can raise folic acid intake without requiring every individual to plan ahead.
The policy has been informed by clinical evidence, expert review, international experience and UK modelling.
None of those points requires us to agree that mandatory fortification is the right method.
Live Beyond the Label does not support adding folic acid by law to most non wholemeal common wheat flour.
Our concern is not the existence of a recognised benefit.
It is the loss of meaningful choice and the limited ability of consumers to understand cumulative intake once fortified flour enters bread, cakes, pastries, biscuits, coatings, soups, gravies, sauces, bakery products, convenience foods and ready meals.
We believe the policy places too much emphasis on population averages and regulatory assurance while giving individuals too little practical information about their own exposure.
If the policy proceeds, responsibility must remain with the authorities and institutions introducing, regulating and evaluating it.
That responsibility should include
– Measuring actual intake rather than relying indefinitely on predictions
– Assessing different age groups separately
– Identifying high consumers
– Monitoring regular supplement users
– Measuring folate and vitamin B12 biomarkers
– Tracking voluntary as well as mandatory fortification
– Publishing results promptly and accessibly
– Explaining uncertainties honestly
– Defining what would trigger a policy review
– Protecting realistic access to unfortified alternatives
– Improving quantitative labelling where reasonably possible
Consumers should not be expected to prove that their cumulative intake remains appropriate when product labels do not usually provide the quantities needed to make that calculation.
Our Final Conclusion
The central question throughout this series has never been whether folic acid can provide a benefit.
It can.
The stronger evidence demonstrates that folic acid supplementation around conception can reduce the risk or recurrence of some neural tube defects. That finding deserves to be recognised and communicated responsibly.
But evidence of benefit does not end the discussion.
The UK has chosen to pursue that benefit by altering a staple ingredient consumed across the population.
That decision brings separate questions about proportionality, cumulative intake, transparency, consumer choice and long term accountability.
The MRC Vitamin Study supported folic acid supplementation around conception among women at high risk.
It did not directly test lifelong exposure through the UK’s modern food supply.
International experience provides useful evidence, but it cannot replace UK specific monitoring.
Population modelling provides valuable predictions, but predictions cannot replace real world measurement.
Labelling folic acid within an ingredients list provides disclosure, but it does not usually show consumers how much a finished product contributes to their total intake.
And the existence of specialist or wholemeal alternatives does not guarantee equivalent, affordable and practical choice across the wider food supply.
Public health and consumer autonomy should not be treated as opposing principles.
A policy can pursue prevention while still being challenged on how it distributes an intervention, informs the public and responds to uncertainty.
At Live Beyond the Label, our position remains clear
A genuine benefit does not remove the need for transparency.
A population-level prediction does not replace individual information.
And monitoring has value only when its findings can lead to action.
The policy should be judged not only by what it intends to achieve, but by what happens after it enters the foods people actually buy and consume.
That means measuring benefits, examining unintended effects, publishing the findings and remaining willing to reconsider the approach.
Because when a nutritional intervention reaches almost everyone, accountability must reach just as far.
